Announcements Trials
Browse Landscape

Status

No longer available 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 285Observational 78Expanded_access 1

Sponsor

Cancer Type

Breast 18Gastrointestinal 5Thoracic 4Genitourinary 4Gynecologic 3Sarcoma 2Head & Neck 2CNS 2Lymphoid 1Endocrine 1Dermatologic 1

Conditions

Melanoma 21Carcinoma, Non-Small-Cell Lung 4Pancreatic Neoplasms 3Ovarian Neoplasms 3Glioblastoma 3Colorectal Neoplasms 3Carcinoma, Basal Cell 3Uveal Melanoma 2Prostatic Neoplasms 2Lymphoma, T-Cell, Cutaneous 2Glioma 2Carcinoma, Merkel Cell 2Carcinoma, Hepatocellular 2Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Skin Neoplasms 1Sarcoma 1Neoplasms 1Lymphoma, Non-Hodgkin 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma 1Liver Neoplasms 1Keratosis 1Hodgkin Disease 1Hematologic Diseases 1Head and Neck Neoplasms 1Esophageal Neoplasms 1Cutaneous or Subcutaneous Tumors Where There is no Comparable or Satisfactory 1Cholangiocarcinoma 1

Interventions

pegilodecakin 1AM0010 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Expanded_access × Breast Neoplasms × Dermatologic × Clear all
NCT03554434 2020-03-02

An Expanded Access Program for AM0010 (Pegilodecakin)

Eli Lilly and Company

No longer available
BreastDermatologicGastrointestinalGenitourinaryGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡